Merck and Moderna's mRNA cancer vaccine hit its Phase 3 trial endpoint, showing improved recurrence-free survival in melanoma ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced ...

Moderna and Merck’s mRNA cancer vaccine, combined with Keytruda, showed promise in preventing melanoma recurrence, according ...

Moderna's personalized mRNA cancer therapy, developed with Merck, reduced the risk of melanoma recurrence and spread in a ...

The vaccine was part of a trial involving patients who’d had surgery to remove melanoma, which can be deadly. The National ...

Moderna's melanoma mRNA vaccine had a major Phase 3 breakthrough. Here's what's next and when it could become available for skin cancer patients.

Moderna's mRNA vaccine combined with Merck's immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the ...

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...

Moderna’s mRNA vaccine combined with Merck’s immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the companies said on Wednesday, ...

New phase 3 results for Moderna and Merck’s personalized mRNA melanoma vaccine support earlier findings showing a 49% lower ...

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big ...

Merck and Moderna say their personalized cancer vaccine reduced melanoma recurrence and spread in a Phase 3 trial.